ATL1103 Acromegaly Phase II Trial Dosing Completed
PR Newswire - Tue Jul 29, 7:00AM CDT
Antisense Therapeutics Limited ("ANP"
Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dl3fhl/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Hospira, Inc. - Athersys, Inc. - GlaxoSmithKline plc - BioLineRx, Ltd. - Novartis AG - Celldex Therapeutics, Inc. - Antisense Therapeutics Limited - Actinium Pharmaceuticals, Inc. - Pharmalink AB - Recoly N.V. - Polyphor Ltd. - Kiadis Pharma B.V. - Bellicum Pharmaceuticals, Inc. - TaiGen Biotechnology Co., Ltd. - TikoMed AB - Tarix Pharmaceuticals LTD. For more information visit http://www.researchandmarkets.com/research/dl...atopoietic
ATL1102 for MS - Toxicology Study Main Findings
PR Newswire - Tue Apr 01, 8:45AM CDT
Antisense Therapeutics Limited ("ANP" or the "Company"
ATL1103 Acromegaly Phase II Trial Recruitment Completed
PR Newswire - Fri Mar 21, 9:00AM CDT
Antisense Therapeutics Limited ("ANP"
ATL1102 for Stem Cell Mobilisation Trial Commencement
PR Newswire - Mon Mar 17, 6:20PM CDT
Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).
Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company"
Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial
PR Newswire - Mon Dec 23, 6:15AM CST
Antisense Therapeutics Limited ("ANP" or "the Company"
ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.
Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path"